DRREDDY - Dr. Reddy's Laboratories Ltd. Share Price

Pharmaceuticals & Biotechnology

Sharesguru Stock Score

DRREDDY

69/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

₹1170.00-8.80(-0.75%)

Market Closed as of Aug 19, 2026, 15:30 IST

Select time range

Pros

Size: It is among the top 200 market size companies of india.

Balance Sheet: Strong Balance Sheet.

Profitability: Recent profitability of 9% is a good sign.

Smart Money: Smart money has been increasing their position in the stock.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Cons

Past Returns: Underperforming stock! In past three years, the stock has provided -0.2% return compared to 8.2% by NIFTY 50.

Momentum: Stock is suffering a negative price momentum. Stock is down -6.9% in last 30 days.

Technicals: SharesGuru indicator is Bearish.

Insider Trading: Significant insider selling noticed recently.

Valuation
Market Cap	96.72 kCr
Price/Earnings (Trailing)	29.95
Price/Sales (Trailing)	2.79
EV/EBITDA	15.46
Price/Free Cashflow	28.93
MarketCap/EBT	24.02
Enterprise Value	1.01 LCr

Fundamentals
Revenue (TTM)	34.65 kCr
Rev. Growth (Yr)	-4.6%
Earnings (TTM)	3.18 kCr
Earnings Growth (Yr)	-69.1%

Profitability
Operating Margin	12%
EBT Margin	12%
Return on Equity	8.33%
Return on Assets	5.48%
Free Cashflow Yield	3.46%

Growth & Returns
Price Change 1W	-1.8%
Price Change 1M	-6.9%
Price Change 6M	-8.8%
Price Change 1Y	-4.3%
3Y Cumulative Return	-0.20%
5Y Cumulative Return	4.1%
7Y Cumulative Return	12.3%
10Y Cumulative Return	6.8%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-6.55 kCr
Cash Flow from Operations (TTM)	5.67 kCr
Cash Flow from Financing (TTM)	829 Cr
Cash & Equivalents	1.54 kCr
Free Cash Flow (TTM)	3.34 kCr
Free Cash Flow/Share (TTM)	40.05

Balance Sheet
Total Assets	58.12 kCr
Total Liabilities	19.89 kCr
Shareholder Equity	38.23 kCr
Current Assets	30.18 kCr
Current Liabilities	16.75 kCr
Net PPE	10.08 kCr
Inventory	7.65 kCr
Goodwill	1.48 kCr

Capital Structure & Leverage
Debt Ratio	0.11
Debt/Equity	0.16
Interest Coverage	8.67
Interest/Cashflow Ops	14.63

Dividend & Shareholder Returns
Dividend/Share (TTM)	8
Dividend Yield	0.69%
Shares Dilution (1Y)	0.00%
Shares Dilution (3Y)	0.20%

Technical Indicators
RSI (14d)	33.7
RSI (5d)	14.67
RSI (21d)	31.44
MACD Signal	Buy
Stochastic Oscillator Signal	Hold
SharesGuru Signal	Sell
RSI Signal	Hold
RSI5 Signal	Buy
RSI21 Signal	Hold
SMA 5 Signal	Sell
SMA 10 Signal	Sell
SMA 20 Signal	Sell
SMA 50 Signal	Sell
SMA 100 Signal	Sell

Description	Share	Value
a) Global Generics	87.0%	7.2 kCr
b) Pharmaceutical Services and Active Ingredients	13.0%	1.1 kCr
Total		8.3 kCr

Shareholder Name	Holding %
LIFE INSURANCE CORPORATION OF INDIA P & GS FUND	12.16%
GVP Family Trust	11.51%
J P Morgan Chase Bank NA	11.41%
VSD Family Trust	9.06%
ICICI PRUDENTIAL VALUE DISCOVERY FUND	4.41%
KALLAM SATISH REDDY HUF	3.31%
NIPPON LIFE INDIA TRUSTEE LTD-A/C-NIPPON INDIA NIFTY 50 VALUE 20 INDEX FUND	1.88%
GUNUPATI VENKATESWARA PRASAD HUF	1.52%
SATISH REDDY KALLAM	1.21%
ANURADHA GUNUPATI	0.01%
GUNUPATI VENKATESWARA PRASAD	0%
SHRAVYA REDDY KALLAM	0%
KALLAM VISHAL REDDY	0%
SHYAMALA GUNUPATI	0%
VSD Holdings & Advisory LLP	0%
APS Trust	0%
SKR Family Trust	0%
KVR Family Trust	0%
Serendipity Family Trust	0%
Malli G Family Trust	0%

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical Industries	4.67 LCr	62.14 kCr	+0.50%	+22.50%	38.58	7.51	-	-
DIVISLAB	Divi's Lab	2.2 LCr	11.68 kCr	+21.40%	+40.30%	75.31	18.86	-	-
CIPLA	Cipla	1.19 LCr	29.16 kCr	+2.00%	-1.20%	35.16	4.07	-	-
LUPIN	Lupin	1.05 LCr	30.44 kCr	-7.90%	+19.90%	19.01	3.45	-	-
AUROPHARMA	Aurobindo Pharma	94.82 kCr	35.62 kCr	+5.30%	+58.10%	25.75	2.66	-	-

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Revenue From Operations	3.2%	33,700	32,644	28,011	24,670	21,545	19,048
Other Income	23.8%	1,358	1,097	894	1,056	484	291
Total Income	3.9%	35,059	33,741	28,905	25,725	22,030	19,339
Cost of Materials	14.4%	6,501	5,684	4,490	4,220	4,312	4,296
Purchases of stock-in-trade	27.3%	6,162	4,841	4,399	3,367	3,484	2,574
Employee Expense	7.4%	5,991	5,580	5,030	4,647	3,886	3,630
Finance costs	32.3%	374	283	171	143	96	97
Depreciation and Amortization	20.8%	2,059	1,704	1,470	1,250	1,165	1,229
Other expenses	5.6%	9,017	8,537	6,839	6,016	6,450	5,469
Total Expenses	13.8%	29,679	26,083	21,719	19,714	19,038	16,503
Profit Before exceptional items and Tax	-29.8%	5,379	7,658	7,186	6,012	2,991	2,836
Total profit before tax	-29.8%	5,379	7,658	7,186	6,012	2,991	2,836
Current tax	-38.3%	1,394	2,258	1,946	814	1,101	817
Deferred tax	47.4%	-159.4	-303.8	-322.8	727	-222.4	115
Total tax	-36.8%	1,235	1,954	1,623	1,541	879	932
Total profit (loss) for period	-27.4%	4,158	5,725	5,578	4,507	2,182	1,952
Other comp. income net of taxes	262.3%	740	205	-65.6	-12.1	-289.8	540
Total Comprehensive Income	-17.4%	4,897	5,930	5,512	4,495	1,893	2,492
Earnings Per Share, Basic	-26.1%	50.41	67.89	67.044	54.294	26.314	23.534
Earnings Per Share, Diluted	-26.1%	50.35	67.79	66.918	54.18	26.242	23.468

Description	(%) Q/Q	Jun-2026	Mar-2026	Dec-2025	Sep-2025	Jun-2025	Mar-2025
Revenue From Operations	7.3%	8,100	7,546	8,753	8,828	8,572	8,528
Other Income	-25.3%	355	475	269	324	290	522
Total Income	5.4%	8,454	8,022	9,022	9,152	8,862	9,050
Cost of Materials	38%	1,654	1,199	1,826	1,441	2,036	1,716
Purchases of stock-in-trade	19.1%	1,974	1,658	1,542	1,746	1,216	1,128
Employee Expense	14.2%	1,652	1,447	1,588	1,452	1,504	1,401
Finance costs	19%	126	106	94	91	83	66
Depreciation and Amortization	-3.6%	537	557	521	505	476	455
Other expenses	-12%	2,203	2,504	2,182	2,243	2,088	2,280
Total Expenses	1%	7,902	7,827	7,481	7,414	6,958	7,051
Profit Before exceptional items and Tax	184%	552	195	1,541	1,738	1,905	2,000
Total profit before tax	184%	552	195	1,541	1,738	1,905	2,000
Current tax	735.6%	158	-23.7	207	185	1,026	432
Deferred tax	-3809.1%	-39.8	2.1	146	223	-531	-13.8
Total tax	617.7%	118	-21.6	354	408	495	418
Total profit (loss) for period	97.7%	436	221	1,190	1,337	1,410	1,587
Other comp. income net of taxes	-37.1%	155	246	177	112	205	109
Total Comprehensive Income	26.6%	591	467	1,367	1,449	1,615	1,696
Earnings Per Share, Basic	162.4%	5.33	2.65	14.53	16.18	17.04	19.12
Earnings Per Share, Diluted	162.4%	5.33	2.65	14.52	16.17	17.02	19.1

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Revenue From Operations	-11.2%	20,533	23,115	19,484	16,962	14,405	13,349
Other Income	68.6%	1,690	1,003	862	591	482	801
Total Income	-7.9%	22,222	24,119	20,346	17,554	14,887	14,150
Cost of Materials	14%	4,332	3,800	3,292	3,161	3,378	3,266
Purchases of stock-in-trade	8%	2,636	2,440	1,987	1,779	2,057	1,252
Employee Expense	8%	3,550	3,288	3,086	2,833	2,435	2,270
Finance costs	34.9%	148	110	22	17	38	47
Depreciation and Amortization	16.2%	1,207	1,039	976	923	814	835
Other expenses	-0.8%	6,328	6,380	5,432	4,845	4,331	3,819
Total Expenses	6.4%	17,971	16,883	14,555	13,688	12,663	11,094
Profit Before exceptional items and Tax	-41.3%	4,251	7,236	5,791	3,866	2,224	3,056
Total profit before tax	-41.3%	4,251	7,236	5,791	3,866	2,224	3,056
Current tax	-48.7%	918	1,790	1,362	864	393	540
Deferred tax	18.9%	114	96	88	389	208	330
Total tax	-45.3%	1,032	1,886	1,449	1,253	601	870
Total profit (loss) for period	-39.8%	3,220	5,349	4,342	2,613	1,623	2,186
Other comp. income net of taxes	-1442%	-117.1	9.8	-31.8	-53.4	51	54
Total Comprehensive Income	-42.1%	3,103	5,359	4,310	2,559	1,674	2,240
Earnings Per Share, Basic	-40.4%	38.68	64.22	52.19	31.474	19.57	26.368
Earnings Per Share, Diluted	-40.4%	38.64	64.13	52.092	31.406	19.516	26.292

Category	DRREDDY	Pharmaceuticals
PE	29.95	38.84
PS	2.79	5.32
Growth	-0.4 %	11.8 %

Description	(%) Q/Q	Jun-2026	Mar-2026	Dec-2025	Sep-2025	Jun-2025	Mar-2025
Revenue From Operations	34.4%	5,137	3,822	4,283	4,619	7,810	5,563
Other Income	-22.4%	440	567	360	364	398	414
Total Income	27.1%	5,577	4,389	4,643	4,983	8,208	5,977
Cost of Materials	16.5%	1,306	1,121	1,067	1,009	1,136	943
Purchases of stock-in-trade	88.5%	902	479	769	724	664	535
Employee Expense	16%	967	834	960	868	887	797
Finance costs	35.8%	73	54	41	33	19	31
Depreciation and Amortization	0%	318	318	314	295	280	264
Other expenses	-11.6%	1,566	1,771	1,518	1,540	1,499	1,763
Total Expenses	8.2%	5,080	4,695	4,539	4,466	4,272	4,416
Profit Before exceptional items and Tax	261.8%	497	-305.5	104	516	3,936	1,562
Total profit before tax	261.8%	497	-305.5	104	516	3,936	1,562
Current tax	142.4%	50	-114.7	13	78	942	364
Deferred tax	46.4%	42	29	0.6	51	33	-3.2
Total tax	204.5%	92	-86.1	14	129	975	361
Total profit (loss) for period	283.3%	405	-219.4	91	387	2,961	1,201
Other comp. income net of taxes	278.2%	99	-54	7	-88.7	18	71
Total Comprehensive Income	283.3%	504	-273.4	98	299	2,980	1,271
Earnings Per Share, Basic	206.3%	4.86	-2.63	1.09	4.65	35.59	14.41
Earnings Per Share, Diluted	206.3%	4.86	-2.63	1.09	4.65	35.54	14.39

Description	(%) Q/Q	Mar-2026	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023
Cash and cash equivalents	55.2%	1,537	991	1,465	1,133	711	1,354
Current investments	-2.5%	3,823	3,922	3,331	3,065	4,405	3,865
Total current financial assets	13.7%	19,536	17,184	15,203	15,125	16,432	14,296
Inventories	0.9%	7,653	7,582	7,108	7,204	6,355	5,659
Current tax assets	-	0	0	0	228	-	30
Total current assets	8%	30,179	27,956	25,018	25,048	24,805	21,770
Property, plant and equipment	10.5%	10,078	9,119	7,298	6,726	6,249	5,850
Capital work-in-progress	-26.9%	1,460	1,997	2,399	1,852	1,351	1,151
Goodwill	5.4%	1,480	1,404	1,314	1,316	550	541
Non-current investments	243.5%	894	261	239	120	106	186
Total non-current financial assets	111.6%	1,186	561	1,127	237	227	259
Total non-current assets	5.8%	27,944	26,417	24,408	21,681	14,058	13,040
Total assets	6.9%	58,123	54,373	49,427	46,728	38,864	34,809
Borrowings, non-current	-	0	0	380	380	380	604
Total non-current financial liabilities	4.1%	1,264	1,214	806	1,017	599	604
Provisions, non-current	-15.4%	34	40	30	0	24	19
Total non-current liabilities	8.6%	3,145	2,896	2,465	2,664	1,021	906
Borrowings, current	40%	6,294	4,496	3,804	4,002	1,272	719
Total current financial liabilities	15.8%	14,250	12,309	10,636	10,765	7,518	6,337
Provisions, current	15.9%	870	751	776	636	692	630
Current tax liabilities	-43%	435	763	303	509	234	398
Total current liabilities	10.9%	16,747	15,104	13,034	12,921	9,588	8,406
Total liabilities	10.5%	19,892	18,000	15,499	15,585	10,609	9,313
Equity share capital	0%	84	84	83	83	83	83
Non controlling interest	-5.6%	339	359	378	394	0	0
Total equity	5.1%	38,231	36,373	33,927	31,143	28,255	25,497
Total equity and liabilities	6.9%	58,123	54,373	49,427	46,728	38,864	34,809

Description	(%) Q/Q	Mar-2026	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023
Cash and cash equivalents	127.7%	338	149	320	98	201	112
Current investments	-1.1%	3,234	3,270	2,883	2,533	4,118	3,584
Loans, current	-	100	0	0	0	0	0
Total current financial assets	-6.9%	11,349	12,196	9,964	10,591	12,183	11,089
Inventories	1.9%	4,956	4,862	4,576	4,568	4,019	3,614
Current tax assets	-	-	-	-	0	-	0
Total current assets	-4.5%	18,523	19,391	16,503	16,945	17,816	16,181
Property, plant and equipment	10.6%	7,753	7,008	5,865	5,442	5,109	4,801
Capital work-in-progress	-19.8%	1,369	1,706	2,156	1,575	1,172	1,048
Goodwill	0%	85	85	85	85	85	85
Non-current investments	10.9%	12,361	11,146	10,310	9,969	3,203	3,303
Loans, non-current	-225%	0.5	1.4	1.4	1.5	62	61
Total non-current financial assets	10.7%	12,630	11,413	11,168	10,057	3,356	3,418
Total non-current assets	8.1%	25,079	23,200	21,788	19,714	12,543	11,806
Total assets	2.4%	43,602	42,591	38,291	36,660	30,359	27,986
Borrowings, non-current	-	0	0	0	0	0	44
Total non-current financial liabilities	-3.1%	250	258	76	48	50	44
Provisions, non-current	0%	12	12	5.4	9.2	9.3	7.9
Total non-current liabilities	10.4%	1,094	991	782	653	580	567
Borrowings, current	48%	5,419	3,663	3,386	3,710	710	36
Total current financial liabilities	17.2%	10,096	8,618	7,532	7,841	4,520	3,649
Provisions, current	8.9%	307	282	340	298	328	298
Current tax liabilities	-78.7%	107	499	79	407	67	179
Total current liabilities	10.5%	11,142	10,087	8,652	9,099	5,538	4,701
Total liabilities	10.5%	12,236	11,078	9,434	9,752	6,118	5,268
Equity share capital	0%	84	84	83	83	83	83
Total equity	-0.5%	31,366	31,513	28,857	26,908	24,241	22,718
Total equity and liabilities	2.4%	43,602	42,591	38,291	36,660	30,359	27,986

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Finance costs	32.3%	374	283	171	143	96	-
Change in inventories	32.5%	-860.1	-1,275.3	-1,844.5	-265.4	-532.8	-
Depreciation	20.8%	2,059	1,704	1,470	1,250	1,165	-
Impairment loss / reversal	108.9%	352	169	0.3	70	930	-
Unrealised forex losses/gains	-369.5%	-52.9	21	-53.3	-92.5	-75.8	-
Adjustments for interest income	-100.4%	0	268	228	118	96	-
Share-based payments	-22%	33	42	41	40	59	-
Net Cashflows from Operations	11.4%	7,399	6,642	6,548	6,959	3,554	-
Interest received	-	-372.6	0	0	0	0	-
Income taxes paid (refund)	-32.3%	1,353	1,999	2,005	1,071	744	-
Net Cashflows From Operating Activities	22.2%	5,674	4,643	4,543	5,887	2,811	-
Cashflows used in obtaining control of subsidiaries	-94.1%	315	5,310	0	0	33	-
Cash payment for investment in partnership firm or association of persons or LLP	-86.8%	5.1	32	1.2	0	0	-
Proceeds from sales of PPE	-40%	31	51	106	8.2	37	-
Purchase of property, plant and equipment	-15.2%	2,331	2,750	1,640	1,132	1,466	-
Proceeds from sales of intangible assets	-	140	0	0	0	295	-
Purchase of intangible assets	119.3%	1,510	689	1,103	754	439	-
Dividends received	-	0	0	44	0	0	-
Interest received	-55.1%	152	337	134	78	87	-
Net Cashflows From Investing Activities	-28.4%	-6,549.3	-5,102.1	-4,028.3	-4,137.1	-2,638.7	-
Proceeds from issuing shares	116.7%	40	19	80	16	33	-
Payments to acquire or redeem entity's shares	-100.7%	0	139	0	0	0	-
Proceeds from borrowings	-17.3%	2,026	2,449	929	0	352	-
Repayments of borrowings	-	0.1	0	380	1,938	0	-
Payments of lease liabilities	-2.3%	126	129	115	102	78	-
Dividends paid	0%	666	666	665	498	415	-
Interest paid	27.7%	444	348	227	185	134	-
Other inflows (outflows) of cash	-	0	0	0	21	0	-
Net Cashflows from Financing Activities	-30.1%	829	1,186	-376.3	-2,686.1	-242.2	-
Effect of exchange rate on cash eq.	485.7%	124	22	-5.9	29	73	-
Net change in cash and cash eq.	-89.7%	78	749	133	-907.3	3.2	-

DRREDDY - Dr. Reddy's Laboratories Ltd. Share Price

DRREDDY

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

DRREDDY - Dr. Reddy's Laboratories Ltd. Share Price

DRREDDY

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

DRREDDY

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Dr. Reddy's Laboratories Ltd. do?

Important Disclosure & Data Context

Valuation

Fundamentals

Profitability

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

DRREDDY

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Dr. Reddy's Laboratories Ltd. do?

Important Disclosure & Data Context